ORGANOGENESIS HOLDINGS INC. Deferred State and Local Income Tax Expense (Benefit)
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Deferred State and Local Income Tax Expense (Benefit) of $2.17 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2026-02-26
- ORGANOGENESIS HOLDINGS INC. deferred state and local income tax expense (benefit) for fiscal 2025 was $2.17M.
- ORGANOGENESIS HOLDINGS INC. deferred state and local income tax expense (benefit) for fiscal 2024 was -$2.55M.
- ORGANOGENESIS HOLDINGS INC. deferred state and local income tax expense (benefit) for fiscal 2023 was -$1.31M.
- ORGANOGENESIS HOLDINGS INC. deferred state and local income tax expense (benefit) for fiscal 2022 was -$3.47M.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $2.17M 10-K · filed 2026-02-26 |
| 2024-12-31 | -$2.55M 10-K · filed 2026-02-26 |
| 2023-12-31 | -$1.31M 10-K · filed 2026-02-26 |
| 2022-12-31 | -$3.47M 10-K · filed 2025-02-27 |
| 2021-12-31 | -$1.47M 10-K · filed 2024-02-29 |
| 2017-12-31 | -$900.00K 10-K · filed 2020-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |